Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Canaccord Genuity downgraded Quanterix Corp. (NASDAQ:QTRX) from Buy to Hold and slashed its price target to $5.00 from $12.00, citing lack of near-term visibility and catalysts. The stock has already fallen over 21% in the past week, with InvestingPro data showing it’s now trading 70% below its 52-week high of $15.86.
The downgrade follows Quanterix’s second-quarter 2025 results reported on August 7, which fell below both Canaccord’s estimates and FactSet consensus expectations. With revenue declining 2.74% and an EBITDA of -$57.17 million in the last twelve months, the company faced increasing headwinds in the biopharma sector and continued uncertainty regarding National Institutes of Health funding.
Quanterix significantly reduced its core Simoa revenue guidance, which now implies a 26% year-over-year decline. The company continues to integrate with spatial biology company Akoya Biosciences amid challenging macro conditions.
Canaccord expressed concern that deal cash flow targets may be at risk, and potential "synergies" could negatively impact top-line growth. The firm believes Quanterix may face a challenging path forward.
The research firm’s revised price target of $5.00, down from $12.00, is based on lowered estimates and DCF (discounted cash flow) analysis.
In other recent news, Quanterix Corporation reported its second-quarter earnings, which fell short of analysts’ expectations. The company’s earnings per share (EPS) came in at -$0.77, missing the forecasted -$0.43. Additionally, Quanterix’s revenue was reported at $24.5 million, below the anticipated $28.23 million. These results highlight a significant miss in both earnings and revenue forecasts. The financial performance of the company is an important consideration for investors, as it provides insight into the company’s current operations and financial health. Analyst reactions to these earnings results have yet to be reported, but such misses can often influence future evaluations. These developments are recent and reflect the company’s current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.